PATH Stock Price Prediction 2026

PATH Stock Forecast in 2026: Quick Answer

UiPath, Inc. (NYSE: PATH) stock was trading at approximately $13.50 as of June 2025. The PATH stock forecast for 2026 ranges from $12–$16 (bear case) to $35–$40 (bull case), with a base case target of approximately $24–$28. (This article is for informational purposes only and does not constitute financial advice.)

2026 PATH stock price prediction summary:

• Current price: Approximately $13.50 as of June 2025. For real-time pricing, check current PATH stock data or your brokerage.
• Bull case: $35–$40. Condition: NRR re-accelerates above 120%, agentic AI contributes measurable ARR, SaaS multiples expand toward 9x forward revenue.
• Base case: $24–$28. Condition: Moderate ARR growth, NRR stabilizes in the 115–118% band, current valuation multiple range holds.
• Bear case: $12–$16. Condition: NRR deteriorates below 110%, Microsoft Power Automate encroaches on mid-market accounts, multiple contracts to 5x forward revenue.
• Analyst consensus price target: Approximately $19 (12-month Wall Street consensus as of mid-2025, per publicly available aggregator data).

Below is a detailed breakdown of the methodology and conditions driving each scenario.

What is UiPath (PATH)? Company Overview

UiPath is an enterprise automation software company that uses Robotic Process Automation (RPA) and AI-powered agents to automate repetitive business processes for large enterprises across sectors including finance, healthcare, and manufacturing. The company trades on the NYSE under the ticker PATH in the Technology sector.

Robotic Process Automation (RPA) uses software bots to automate repetitive, rule-based digital tasks that were previously performed by human workers, such as data entry, invoice processing, and compliance checks. UiPath leads the RPA market ahead of Automation Anywhere and Blue Prism. The global RPA market is projected to reach approximately $20–$25 billion by 2027 (Gartner/IDC), giving UiPath significant runway beyond its current revenue base.

UiPath was founded in 2005 in Bucharest, Romania, by co-founders Daniel Dines and Marius Tîrcă, and later redomiciled to New York. The company went public on April 21, 2021, at $56 per share, opened near $65 on its first trading day, and peaked near $90 in May 2021. Its business model runs on Annual Recurring Revenue (ARR), the total value of contracted recurring subscription revenue normalized to a one-year period and UiPath's core measure of business scale. The company has been transitioning away from perpetual licenses to a cloud and SaaS subscription structure. UiPath's platform components include Studio (bot development), Orchestrator (deployment management), and AI Agents (the agentic automation layer).

Important: UiPath Fiscal Year. UiPath's fiscal year ends January 31, not December 31. FY2026 covers February 1, 2025 through January 31, 2026. FY2027 covers February 1, 2026 through January 31, 2027. All financial figures in this article specify which fiscal year they reference.

Daniel Dines and the 2024 Leadership Signal

Daniel Dines, UiPath's co-founder, temporarily stepped back from day-to-day CEO responsibilities before returning to the role in 2024. For investors evaluating the 2026 outlook, this return is a specific signal beyond biography: founder-led enterprise software companies have historically shown stronger performance when the founding CEO returns with renewed strategic focus, particularly when that return coincides with a product pivot. Dines' return aligned directly with UiPath's push into agentic AI, sharpening the company's product strategy around the orchestration of AI agents within enterprise workflows. That strategic clarity is a meaningful input to the bull case.

With UiPath's business model and leadership context established, the following section examines where PATH stock has traded since its 2021 IPO.

PATH Stock Price History and Recent Performance

PATH shares were trading at approximately $13.50 as of June 2025. For real-time pricing, check current PATH stock data or your brokerage.

[PATH historical price chart: IPO date to present, showing 2021 peak near $90 and 2022–2023 trough near $10–$14. Source: Yahoo Finance. Data as of June 2025.]

PATH launched at $56 per share on April 21, 2021, opened near $65, and peaked near $90 in May 2021 as investor enthusiasm for high-growth SaaS reached its post-pandemic high. The decline that followed was steep and prolonged.

UiPath's stock fell from its 2021 highs because rising interest rates in 2022 compressed growth stock valuation multiples broadly, UiPath-specific ARR growth decelerated as enterprise customers rationalized software spending, and Net Revenue Retention came under pressure as existing customers reduced their automation deployment scope. PATH dropped to lows of approximately $10–$14 per share through 2022 and 2023, a fall of roughly 85% from the all-time high.

The stock began a partial recovery from its 2023 lows, trading back into the mid-teens by mid-2025. PATH has not recovered to IPO-era prices. As of June 2025, the stock sits approximately 85% below its all-time high. The 52-week range spans approximately $9.50 (low) to $17.50 (high).

Chart Signals (technical context only): PATH's 50-day moving average sits below the 200-day moving average as of mid-2025, a configuration that technicians characterize as bearish. The RSI reading near 45 suggests neutral territory, neither overbought nor oversold. Key support sits near $11.50; resistance near $16.

The 2026 forecast must be evaluated against a stock still trading far below its 2021 highs. Bull case targets of $35–$40 represent meaningful upside from current levels, even if they fall well short of IPO-era valuations.

With historical price context established, here is how Wall Street analysts currently rate PATH stock.

PATH Stock Analyst Ratings and Price Targets

Wall Street analysts hold a predominantly cautious-to-neutral view on PATH stock, with a consensus price target of approximately $19, representing roughly 41% upside from the current price near $13.50 as of mid-2025.

Data sourced from publicly available analyst consensus data for PATH. Data current as of June 2025. Verify all figures before making investment decisions.

Analyst ratings break down to roughly 4 Buy or Overweight, approximately 5 Hold or Neutral, and no current Sell ratings in the primary coverage set. Targets span from $14 (Barclays, reflecting caution on NRR pressure) to $28 (Needham, reflecting conviction in agentic AI re-acceleration). The consensus average of approximately $19 implies modest upside from current levels but falls well short of the bull case modeled in the following section.

These are 12-month Wall Street analyst price targets based on fundamental research. They differ from algorithmic model outputs produced by tools like Macroaxis or WalletInvestor, which generate forecasts from statistical patterns rather than business analysis. Wall Street targets carry substantially greater credibility for investment decision purposes.

Beyond analyst consensus, the following section presents our own bull, base, and bear price scenarios for PATH in 2026 with explicit EV/Revenue methodology.

PATH Stock Price Forecast 2026: Bull, Base, and Bear Scenarios

The following price scenarios are derived using an EV/Revenue framework: Enterprise Value (market capitalization plus net debt) divided by projected FY2027 revenue (ending January 31, 2027), adjusted for UiPath's net cash position and diluted share count, to produce an implied stock price per share. The three scenarios reflect different combinations of ARR growth trajectory, NRR trend, and market valuation multiple. Assumptions include approximately $1.7 billion net cash and approximately 570 million diluted shares outstanding.

These scenarios are illustrative projections based on publicly available financial data and analyst estimates. They are not guarantees of future performance. Data current as of June 2025.

Bull Case: PATH Stock Price Forecast 2026

Under bull case conditions, PATH stock could trade at approximately $35–$40 by end of calendar 2026. This scenario assumes UiPath achieves FY2027 revenue of approximately $1.85 billion (ending January 31, 2027), implying roughly 15% growth from FY2026, and that the market re-rates PATH to a 9x forward revenue multiple from its current 6–7x range.

Three specific conditions drive this outcome. First, Net Revenue Retention re-accelerates above 120% as agentic AI upsell cycles take hold in existing enterprise accounts; customers that deployed traditional RPA bots begin expanding into agentic AI workflow deployments, driving expansion ARR. Second, UiPath's Agentic Automation platform generates a named ARR contribution that management discloses in quarterly earnings, signaling that the strategic pivot is producing commercial returns. Third, broader SaaS multiples expand modestly as Federal Reserve rate normalization reduces the discount rate applied to growth stock cash flows, supporting a re-rating toward ServiceNow-tier multiples for higher-quality SaaS names.

Investors who hold the bull view argue that UiPath's deep enterprise customer relationships give it a first-mover advantage in deploying agentic AI at scale. A PATH price of $30 by end of 2026 is achievable under base-to-bull case conditions, requiring NRR stabilization and at least modest multiple expansion from current levels.

Base Case: PATH Stock Price Forecast 2026

The base case projects PATH stock at approximately $24–$28 by end of calendar 2026, based on FY2027 revenue of approximately $1.65 billion and a 7x forward revenue multiple, consistent with current market pricing for a software company growing in the mid-to-high single digits.

Three baseline assumptions underpin this scenario. ARR grows at a moderate 7–8% rate year-over-year, and NRR stabilizes in the 115–118% band without materially re-accelerating or deteriorating. Agentic AI adds incremental ARR but has not yet produced a step-change in UiPath's overall growth trajectory. SaaS valuation multiples stay range-bound as the macro environment remains neither strongly supportive nor disruptive to growth stock sentiment.

Under base case conditions, PATH trades at a discount to SaaS peers but with a credible path to re-rating if execution improves. This scenario reflects the most likely outcome if UiPath continues at its recent operating pace without a breakout catalyst.

Bear Case: PATH Stock Price Forecast 2026

In a bear scenario, PATH stock could trade at approximately $12–$16 by end of calendar 2026, near or below current levels. This scenario assumes FY2027 revenue stalls at approximately $1.45 billion (growth of 2–3%) and the market assigns a 5x forward revenue multiple, reflecting a reassessment of UiPath's competitive position.

Two primary triggers drive the bear case, compounded by a third amplifying factor. NRR falls below 110%, signaling that existing customers are net-contracting their automation spend; this is the most direct evidence of Microsoft Power Automate displacement in mid-market accounts. Simultaneously, the Agentic Automation platform fails to generate meaningful ARR by mid-2026, causing investors to view the AI pivot as a cost center rather than a revenue catalyst. The amplifying factor: macro headwinds (enterprise IT budget freezes or sustained higher interest rates) compress SaaS multiples broadly, penalizing companies with UiPath's growth profile.

These scenarios are illustrative projections based on publicly available financial data and analyst estimates. Actual PATH stock prices may differ substantially from any scenario outlined here.

The scenarios above rest on specific assumptions about UiPath's financial trajectory. The following section examines the underlying fundamental data that either supports or challenges each case.

UiPath Fundamental Analysis: ARR, NRR, Rule of 40, and Valuation

UiPath's most closely watched financial metrics, including ARR growth, NRR trend, free cash flow margin, and the Rule of 40, collectively tell investors whether the company's underlying business quality supports or undermines the 2026 price scenarios above.

Annual Recurring Revenue (ARR): UiPath's Growth Engine

Annual Recurring Revenue (ARR) represents the total value of contracted recurring subscription revenue normalized to a one-year period, distinct from total GAAP revenue, which includes one-time and legacy license fees. ARR is the metric investors weight most heavily when modeling UiPath's forward trajectory.

As of Q3 FY2025 (ending October 31, 2024), UiPath reported ARR of approximately $1.61 billion, per UiPath quarterly earnings reports. ARR grew approximately 17% year-over-year in Q3 FY2025, a deceleration from the 24%-plus growth rates posted in fiscal 2023. Total revenue for FY2025 (ending January 31, 2025) was approximately $1.31 billion.

The deceleration is the central investor concern. To support the base case valuation of $24–$28, UiPath needs ARR to reach approximately $1.65 billion in FY2027 (ending January 31, 2027). The bull case requires ARR closer to $1.85 billion, implying a re-acceleration. The bear case assumes ARR growth nearly stalls at $1.45 billion. ARR trajectory heading into calendar 2026 is the single most important variable investors should track.

Net Revenue Retention (NRR): The Key Investor Watch Metric

Net Revenue Retention (NRR) measures the percentage of revenue retained from existing customers over a 12-month period, accounting for expansions, contractions, and churn. An NRR above 100% means existing customers are collectively spending more than they were a year ago. UiPath also reports this metric as Net Dollar Retention (NDR); both terms are synonymous.

UiPath's NRR has trended in the 115–118% range in recent quarters, per UiPath quarterly earnings reports. That figure confirms net expansion, but represents a meaningful deceleration from the 120%-plus NRR levels posted during UiPath's peak growth phase in fiscal 2022 and 2023. The trend over the past four quarters shows NRR drifting slightly lower, not yet recovering.

Why does this matter for PATH's 2026 stock price? Re-acceleration above 120% would signal that agentic AI upsell cycles are working and that existing customers are expanding their automation footprint, a primary bull case enabler that would support multiple expansion. Further erosion toward 110% would signal customers reducing spend, likely driven by competitive substitution, the direct trigger for bear case multiple contraction.

Investors should track NRR in smaller customer cohorts specifically. Sustained deterioration in those segments is the clearest signal of Microsoft Power Automate encroachment, and this metric receives far less attention in most available PATH analysis than its significance deserves.

Valuation: Is PATH Cheap or Expensive?

EV/Revenue multiple (Enterprise Value divided by annual revenue) is the standard valuation metric for software companies. It tells investors how much the market pays for each dollar of revenue, enabling comparisons across companies at different profitability stages. Unlike the P/E ratio, which requires positive earnings, EV/Revenue applies to growth-stage companies like UiPath regardless of GAAP profitability.

PATH currently trades at approximately 6–7x forward revenue, based on an enterprise value of approximately $8–$9 billion and FY2026 revenue estimates near $1.35–$1.40 billion as of mid-2025. For context, ServiceNow (NYSE: NOW) trades at approximately 14–15x forward revenue and Salesforce (NYSE: CRM) at approximately 7–8x. PATH sits at a discount to ServiceNow's premium multiple but at rough parity with Salesforce, reflecting PATH's slower growth and recovery-stage positioning. High-growth SaaS companies with 20%-plus revenue growth and positive free cash flow have historically traded at 8–15x forward revenue; companies in UiPath's current growth range typically trade at 5–8x, placing PATH near the upper end of its appropriate band.

Whether PATH is undervalued depends on the growth scenario. Investors who believe the bull case will play out argue the stock deserves an 8–9x multiple; those who see the bear case as more likely argue the current 6–7x multiple already prices in too much optimism for a company with decelerating growth.

Rule of 40 and Free Cash Flow

The Rule of 40 is a SaaS health benchmark calculated by adding a company's revenue growth rate (%) to its free cash flow margin (%). A combined score above 40 is considered healthy for a growth-stage software company.

UiPath's Rule of 40 score stands at approximately 31–33 as of Q3 FY2025, composed of roughly 17% ARR growth and approximately 14–16% free cash flow (FCF) margin. The score has shown modest improvement over the past four to six quarters, rising from the mid-20s range as FCF margins have expanded. Free cash flow (FCF) margin measures the percentage of revenue that converts to actual cash after operating expenses and capital expenditures. A positive and rising FCF margin signals the business is becoming more self-funding.

UiPath is not yet GAAP profitable due to stock-based compensation expenses, but has achieved positive non-GAAP operating income and positive free cash flow, a distinction that matters for investors evaluating whether UiPath is a cash-burning business. The company generates real cash. A Rule of 40 score consistently above 40 would support multiple expansion toward 8–9x forward revenue and represents the financial improvement signal most likely to trigger a valuation re-rating in 2026.

Source: UiPath quarterly earnings reports. Data current as of June 2025. Verify all figures before making investment decisions.

Taken together, UiPath's fundamentals show a business generating positive free cash flow with ARR growth decelerating. The question for 2026 investors is whether NRR recovery and agentic AI monetization can re-accelerate ARR growth to support the 7–9x valuation multiple range implied by the base and bull cases.

Those fundamental dynamics play out against a competitive backdrop that will determine whether UiPath can defend and expand its customer base through 2026.

UiPath Competitive Position: Microsoft, Automation Anywhere, and ServiceNow

UiPath faces competitive pressure on three distinct fronts: Microsoft Power Automate in the mid-market, Automation Anywhere in large enterprise RPA, and ServiceNow in AI-powered workflow automation.

Microsoft Power Automate: The Primary Mid-Market Threat

Microsoft Power Automate poses a genuine threat to UiPath in specific customer tiers, but the competitive risk is segmented, not existential.

Power Automate is included in Microsoft 365 subscriptions at no additional cost, giving it a zero-incremental-cost distribution advantage in SMB and lower-enterprise customers who already pay for M365. This bundled model most threatens UiPath in sub-$100K ARR accounts, where the cost savings from switching to Power Automate outweigh the migration friction and retraining costs. For these customers, the rational economic calculation often favors Microsoft.

In complex large-enterprise deployments requiring multi-system orchestration, compliance-grade reliability, and bot management at scale, Power Automate lacks the depth UiPath delivers. UiPath's enterprise moat is strongest precisely where deployment complexity is highest. The competitive threat is real but concentrated at the lower end of the enterprise customer stack.

Investors should watch UiPath's NRR in smaller customer cohorts. Deterioration below 110% in those segments would signal accelerating Microsoft substitution.

Automation Anywhere and the Enterprise RPA Battle

Automation Anywhere is UiPath's most direct enterprise RPA competitor. As a private company headquartered in San Jose, the lack of public financial disclosures limits direct comparison. It competes with UiPath for large enterprise RPA contracts, particularly in financial services and insurance, and has pivoted toward AI-powered automation, making the enterprise competitive environment more dynamic. Microsoft remains the more immediate threat to PATH's financial metrics in 2026. Blue Prism, now part of SS&C Technologies, represents the legacy RPA generation and is less relevant to UiPath's current competitive position.

ServiceNow: Competitor and Valuation Peer

ServiceNow (NYSE: NOW) plays a dual role in evaluating PATH. As a competitor, ServiceNow's Now Platform increasingly incorporates AI-powered workflow automation that overlaps with UiPath's enterprise use cases, particularly as both companies pursue agentic AI orchestration. ServiceNow's primary market remains IT service management, but the product boundaries are blurring. As a valuation benchmark, ServiceNow trades at approximately 14–15x forward revenue, a premium multiple reflecting faster growth and higher profitability. PATH would need sustained ARR re-acceleration above 20% and Rule of 40 improvement above 40 before the market would apply ServiceNow-tier multiples.

UiPath's defensibility in the 2026 time horizon hinges most on NRR trajectory in its mid-market customer base. That single metric will reveal whether Microsoft's bundled advantage is materially displacing UiPath or whether UiPath's enterprise moat is holding.

That competitive dynamic shapes the specific risk factors that could prevent the base or bull case from materializing.

PATH Stock Risk Factors: What Could Derail the 2026 Thesis?

Any bull case for PATH in 2026 carries meaningful risks. Here are the five factors investors should monitor most closely.

1. Microsoft Competitive Displacement. Microsoft Power Automate's bundled M365 distribution makes substitution economically rational for UiPath's smaller enterprise customers. The measurable signal is NRR deterioration in sub-$100K ARR cohorts. If UiPath's NRR in those segments falls below 110%, the mid-market moat is eroding faster than the company can move upmarket.

2. NRR Deterioration Below 110%. NRR at that level signals customers are net-contracting their automation spend, a direct multiple compression trigger. The growth narrative collapses and PATH would likely trade toward the bear case multiple of 5x forward revenue. No single metric carries more weight in PATH's 2026 thesis than NRR direction.

3. Agentic AI Execution Failure. The bull case depends heavily on the Agentic Automation platform converting to measurable ARR by mid-2026. If UiPath's earnings disclosures through H1 2026 show no specific agentic AI revenue contribution, investors will question whether the strategic pivot is generating returns or simply incurring product development costs. The risk is not technical failure but slow enterprise adoption cycles.

4. Valuation Multiple Contraction and Macro Headwinds. Higher-for-longer interest rates compress SaaS valuation multiples. A recession-driven enterprise IT budget freeze would simultaneously reduce new customer acquisition and accelerate churn in price-sensitive accounts, pressuring the revenue assumption and the multiple at the same time.

5. Leadership Concentration Risk. Daniel Dines' return as CEO in 2024 is a positive investment signal, but it concentrates strategic decision-making in one individual. Any leadership disruption or C-suite instability would be a negative re-rating catalyst, particularly given UiPath's history of leadership transitions between 2022 and 2024.

NRR trend and Microsoft competitive dynamics in the mid-market are the two highest-priority monitoring metrics for PATH investors in 2026. They are the leading indicators for whether the base case holds or the bear case takes over.

Against these risks, UiPath's agentic AI platform represents the single most important potential catalyst, which the following section examines in detail.

UiPath and Agentic AI: The 2026 Growth Catalyst

AI is reshaping UiPath's business in two simultaneous ways: as a demand tailwind that increases enterprise automation budgets, and as a product evolution imperative that requires UiPath to extend its platform from rule-based RPA into AI-orchestrated autonomous workflows.

Agentic AI refers to AI systems capable of autonomously planning and executing multi-step tasks with minimal human supervision, going beyond rule-based bots to AI that can reason and make decisions across complex enterprise workflows. This is distinct from generative AI tools like chatbots or image generators. UiPath's agentic AI pitch is about orchestrating autonomous agents within enterprise processes, not building foundation models.

UiPath launched its UiPath Agentic Automation platform in 2024, positioning the company as the orchestration layer connecting human workers, traditional RPA bots, and AI agents within enterprise workflows. The platform allows enterprises to deploy AI agents that execute multi-step processes autonomously, replacing or augmenting the rule-based bots that formed UiPath's original product. UiPath integrates with leading large language models, including OpenAI's GPT models, Google Gemini, and Anthropic Claude, to power these AI-augmented features. UiPath is not building its own foundation models; it is building the enterprise workflow orchestration layer that deploys third-party LLMs within controlled business processes.

Enterprise spending on AI software is projected to grow at approximately 20–25% CAGR through 2027 (Gartner, 2024), creating demand for companies serving as the orchestration layer between enterprise workflows and AI models. The global RPA market is projected to reach approximately $20–$25 billion by 2027 (Gartner/IDC), with UiPath's current ARR representing a fraction of the total addressable opportunity.

The bull case connection is direct: if enterprise customers accelerate agentic AI adoption, UiPath's existing RPA customer base becomes an expansion opportunity. Customers that already deploy UiPath's bots can add agentic AI workflow capabilities, driving ARR expansion and potentially lifting NRR back above 120%. This is the specific mechanism by which agentic AI could re-accelerate ARR growth and NRR, supporting the bull case valuation of $35–$40.

The execution risk is equally specific. UiPath must monetize agentic AI before Microsoft's Copilot platform, ServiceNow's Now Assist, or AI-native competitors capture the enterprise orchestration layer. UiPath holds the advantage of deep enterprise customer relationships and process expertise built over 15 years, but time-to-revenue matters, and enterprise AI adoption cycles have historically moved more slowly than technology companies anticipate.

Investors should watch for explicit agentic AI ARR contribution disclosures in UiPath's quarterly earnings. A named revenue line for agentic AI in 2025 or early 2026 would be a meaningful bull signal; its absence through H1 2026 would raise execution questions.

With catalysts and risks both quantified, the following section synthesizes the analysis into a framework for evaluating whether PATH fits an individual investor's thesis.

Is PATH Stock a Good Investment in 2026?

Whether PATH is a good investment in 2026 depends on your investment thesis and time horizon. Investors who believe UiPath will successfully monetize its agentic AI platform and that NRR will stabilize or recover may find the current valuation attractive relative to the bull case price target. Investors concerned about Microsoft's mid-market encroachment, ongoing NRR pressure, or the execution risk of the agentic AI pivot may prefer to wait for additional confirmation before committing capital.

For growth-oriented investors with a 12–18 month horizon and tolerance for volatility, PATH presents a specific bet: that the agentic AI platform will produce measurable ARR by mid-2026 and that NRR will stabilize above 115%. At approximately 6–7x forward revenue, PATH sits at a discount to most SaaS peers, offering re-rating upside if the execution thesis plays out.

For risk-aware investors with lower risk tolerance, near-term liquidity needs, or skepticism about agentic AI monetization timelines, the bear case ($12–$16) represents a scenario where the stock barely moves from current levels or declines further. These investors may prefer to monitor NRR trajectory for two or three quarters before committing capital.

The three metrics most worth monitoring through 2026: (1) NRR trajectory, specifically whether it stabilizes above 115% or continues declining toward 110%; (2) Agentic AI ARR contribution, whether UiPath begins disclosing specific revenue from its Agentic Automation platform in quarterly earnings; (3) Rule of 40 score trend, whether the combined growth-plus-FCF-margin score is approaching or crossing 40.

This article is for informational purposes only and does not constitute financial advice. Always conduct your own due diligence before making investment decisions.

For answers to the most common questions about PATH stock in 2026, see the FAQ section below.

Frequently Asked Questions: PATH Stock in 2026

What is the PATH stock price prediction for 2026?

The PATH stock price prediction for 2026 ranges from approximately $12–$16 (bear case) to $35–$40 (bull case), with a base case target of approximately $24–$28. These scenarios are derived using an EV/Revenue methodology applied to projected FY2027 revenue (ending January 31, 2027) at different valuation multiples. For the full scenario methodology, see the PATH Stock Price Forecast 2026 section above.

Is PATH stock a good buy right now?

Whether PATH is a good buy right now depends on your investment horizon and risk tolerance. Investors with a 12–18 month horizon who believe UiPath's agentic AI platform will re-accelerate ARR growth may find current valuations attractive near 6–7x forward revenue. Those concerned about NRR pressure and Microsoft competition may prefer to wait for catalyst confirmation in upcoming earnings. Always conduct your own research before making investment decisions.

What do analysts think about UiPath stock?

Wall Street analysts hold a cautious-to-neutral consensus on PATH, with an average price target of approximately $19 as of mid-2025, representing roughly 41% upside from current levels near $13.50. Piper Sandler and Needham carry the most bullish targets at $25 and $28 respectively, while Morgan Stanley, Goldman Sachs, and Barclays reflect more cautious views in the $14–$16 range. For the full breakdown, see the PATH Stock Analyst Ratings section above.

Is UiPath stock risky?

PATH carries above-average risk compared to established large-cap stocks, due to its growth-stage valuation near 6–7x forward revenue, competitive pressure from Microsoft Power Automate in the mid-market, dependence on enterprise software spending trends, and the execution risk of its agentic AI pivot. Investors with a low risk tolerance should carefully evaluate position sizing. For a detailed breakdown, see the PATH Stock Risk Factors section above.

Can PATH stock go to zero?

A PATH stock price of zero would require UiPath to become insolvent, which is not a near-term risk given the company's positive free cash flow and substantial cash reserves. The bear case for PATH is not business failure but rather stock price compression from slower growth and valuation multiple contraction, potentially to the $12–$16 range. Bear case analysis assumes continued operation, not insolvency.

What does UiPath do?

UiPath is an enterprise automation software company that uses Robotic Process Automation (RPA) and AI-powered agents to automate repetitive business tasks for large enterprises across sectors like finance, healthcare, and manufacturing. The company launched its agentic AI platform in 2024, positioning itself as the orchestration layer connecting traditional RPA bots and AI agents within enterprise workflows. For a full overview, see the What is UiPath company overview section above.

Is PATH a buy, hold, or sell?

According to publicly available analyst consensus data as of mid-2025, approximately 4 analysts rate PATH Buy or Overweight, approximately 5 rate it Hold or Neutral, and none carry a Sell rating in the primary coverage set. The consensus leans neutral with a meaningful bullish minority. Investors should frame the buy/hold/sell question through the bull/base/bear scenarios, since the answer depends on which conditions they believe are most likely to materialize. Always conduct your own due diligence before making investment decisions.

Will PATH stock go up in 2026?

PATH stock has upside potential in 2026 if NRR stabilizes or recovers above 115%, agentic AI begins contributing measurable ARR, and SaaS valuation multiples stay supportive. Under the base case, PATH could trade at approximately $24–$28 by end of calendar 2026, roughly double current levels. Downside risk exists if NRR deteriorates below 110% or the agentic AI thesis fails to produce revenue evidence. Always conduct your own research before making investment decisions.

What is the highest price PATH stock has ever been?

PATH's all-time high was approximately $90 per share, reached in May 2021 shortly after its IPO at $56 per share on April 21, 2021. The stock subsequently declined to lows of approximately $10–$14 during the 2022–2023 tech growth selloff. Current 2026 bull case targets of $35–$40 represent meaningful upside from current levels but remain well below IPO-era highs.

Should I buy PATH stock in 2025?

Investors targeting a 2026 price objective may consider building a position in 2025 to allow time for catalysts to develop, particularly if NRR shows early signs of stabilization and agentic AI ARR begins appearing in UiPath's earnings disclosures. Entry timing depends on individual risk tolerance and current market conditions. This article is for informational purposes only and does not constitute financial advice.

Always conduct your own due diligence and consider consulting a qualified financial advisor before making investment decisions.

Investment Disclaimer

This article is for informational purposes only and does not constitute financial advice, investment advice, or a recommendation to buy or sell any security. The price scenarios and analysis presented are based on publicly available information and are subject to change without notice. Past performance is not indicative of future results. Stock investing involves risk, including the possible loss of principal. Always conduct your own due diligence and consider consulting a qualified financial advisor before making investment decisions. The author does not hold a position in PATH stock as of the publication date of this article.

Financial data in this article is current as of June 2025. Stock prices, analyst ratings, and company financial metrics change frequently. Verify all figures before making investment decisions.